$DRIO NEWS: DarioHealth Announces Alliance with

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
362
$DRIO NEWS: DarioHealth Announces Alliance with DigitalHealth.London As Part of the UK Israel Dangoor Health Initiative

PR Newswire•August 15, 2019
- DarioHealth's innovative digital therapeutics solutions will assist the UK National Health Service with managing chronic health conditions, such as diabetes and hypertension

NEW YORK and CAESAREA, Israel, Aug. 15, 2019 /PRNewswire/ -- DarioHealth Corp. ("DarioHealth" or "Dario" (DRIO), a leading, global digital therapeutics company, today announced an alliance with DigitalHealth.London ("DH.L" as part of its UK Israel Dangoor Health Initiative (the "Initiative" , which aims to partner leading Israeli digital health companies with the UK National Health Service (NHS) to benefit patients.

Dario was selected by DH.L to help bring its highly regarded digital therapeutics technology to assist NHS patients in better managing their chronic health conditions, such as pre-diabetes, diabetes and hypertension, among other chronic conditions.

The Initiative is a partnership between the UK Israel Tech Hub, which aims to help British companies partner with cutting-edge technology companies in Israel; DigitalHealth.London, a collaborative that helps high-potential, digital health start-up companies connect with the NHS; and Dangoor Education.

DH.L is well placed to accelerate the adoption and scaling of digital innovations across the NHS. The Initiative will help facilitate additional access for DarioHealth to key UK clinicians, academic institutes, healthcare system experts and industries in order to better understand the needs of patients and the NHS.

"With 25 per cent of middle-aged adults suffering from hypertension and 2.6 million people diagnosed with diabetes, the NHS needs the very best in digital innovation in order to manage chronic disease conditions successfully, now and into the future," said Dror Bacher, Chief Operating Officer at DarioHealth Corp. "I recently had the pleasure of meeting key NHS clinicians and influencers and learned first-hand about the challenges and opportunities that they're experiencing within the healthcare sector. DarioHealth is well positioned to offer quality digital therapeutic interventions for managing chronic conditions and looks forward to exploring opportunities for integration and partnership with both primary and secondary care providers. Through our collaboration, we will examine the best ways to develop new Dario digital therapeutic solutions for people with chronic conditions within the framework of the NHS."

A key differentiator of Dario's performance-based platform is its emphasis on behavioral engagement with users, through the offering of personalised interventions, which is a unique approach in the digital therapeutics' arena. DarioHealth's platform focuses on the user's needs, experience and satisfaction. We believe that this approach disrupts the traditional approach used by most healthcare companies and makes the Dario platform the most popular product by people managing diabetes and pre-diabetes.

DarioHealth continues to find new, innovative ways to assist its users in improving their health through ongoing analysis of clinical-data studies and the application of new digital solutions. By delivering personalized, evidence-based interventions driven by precision data analytics, high-quality software and personalised coaching, DarioHealth has a dynamic health management approach that empowers individuals to make informed, data-driven choices that improve their short and long-term health. Dario's membership programs offer professional coaching to individuals with pre-diabetes, diabetes and hypertension to provide them a clear and timely view of their condition in a user-friendly format directly on their iPhone or Android mobile device.

DarioHealth's most recently introduced digital product, the Dario Blood Pressure Monitoring System™, assists hypertension patients in managing their blood pressure throughout the day, further solidifying the company's presence in the hypertension management market.

About DarioHealth Corp.

DarioHealth Corp. (DRIO) is a leading, global digital therapeutics company revolutionising the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric Dario mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions via the Dario mobile app, please go to: http://mydario.com/

DarioHealth Corp. (DRIO) Stock Research Links

DRIO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 578

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 159

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 63

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 117

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 181

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 222

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 469

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 150

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading

Top 5 Most Recently Viewed Articles

CleanSpark's $550 Million Notes Offering and Strategic Outlook

Updated Category News Views 320

CleanSpark, Inc. Unveils $550 Million Convertible Notes Offering CleanSpark, Inc. (NASDAQ: CLSK), a leader in Bitcoin mining, has announced the successful pricing of a significant offering of $550 million in aggregate principal amount of its 0.00% Convertible Senior Notes due 2030. This endeavor is strategically positioned to enhance the company's financial flexibility...

Continue Reading
Terviva and Idemitsu Team Up for Sustainable Aviation Innovation

Updated Category News Views 203

Terviva Partners with Idemitsu for Sustainable Aviation Fuels Terviva, Inc. is a trailblazer in agricultural innovation, working to cultivate pongamia, a highly sustainable crop, for various applications including food, feed, and fuel. Recently, Terviva has entered into a strategic partnership with Idemitsu Kosan Co., Ltd, a leader in integrated energy, to advance the...

Continue Reading
Transforming Invoice Processing: BERNER Group Adopts xSuite

Updated Category News Views 362

Transforming Invoice Processing at BERNER Group The SAP-certified, highly integrated solution meets all the requirements of German and European legislation on electronic invoices. In a significant move towards modern procurement efficiency, the BERNER Group has chosen to adopt xSuite's AI-driven invoice automation solution. This innovative decision aligns with their...

Continue Reading
Celebrating Gord Hicks: A Commitment to Youth Wellness

Updated Category News Views 265

Honoring Gord Hicks with the King Charles III Coronation Medal Gord Hicks C.M., the CEO of BGIS, has been honored with the King Charles III Coronation Medal, recognizing his extensive commitment to youth mental health advocacy. For a decade, Hicks has actively supported initiatives with Kids Help Phone, contributing significantly to the well-being of young Canadians. The...

Continue Reading
Cellebrite Sees Booming Growth with Higher Price Target Outlook

Updated Category News Views 224

Cellebrite's Growth Prospects Shine Brightly Recently, TD Cowen raised its price target for Cellebrite (NASDAQ: CLBT) shares from $20.00 to $23.00, signaling the company's strong growth potential. This update reflects an optimistic outlook that emerged from recent management discussions, which provided valuable insights into Cellebrite's strategic direction and market...

Continue Reading